FILGOTINIB, A SELECTIVE JANUS KINASE 1 (JAK1) INHIBITOR, MODULATES DISEASE-ASSOCIATED CYTOKINES IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS

被引：0
|
作者：
Taylor, Peter C. [1 ]
Elboudwarej, Emon [2 ]
LI Wanying [2 ]
Hawtin, Rachael E. [2 ]
Liu, Jinfeng [2 ]
Mirza, Amer M. [2 ]
机构：
[1] Univ Oxford, Botnar Res Ctr, Oxford, England
[2] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.2510
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0133
引用
收藏
页码：736 / 736
页数：1
相关论文
共 50 条
  • [31] SAFETY AND EFFICACY OF ABT-494, A NOVEL SELECTIVE JAK1 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
    Genovese, M. C.
    Smolen, J. S.
    Weinblatt, M. E.
    Meerwein, S.
    Camp, H. S.
    Wang, L.
    Othman, A. A.
    Khan, N.
    Jungerwirth, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 141 - 142
  • [32] Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis
    Zhang, Ning
    Zhang, Changqing
    Zeng, Zhihong
    Zhang, Jiyong
    Du, Shengnan
    Bao, Chunde
    Wang, Zhe
    JOURNAL OF INFLAMMATION RESEARCH, 2021, 14 : 2133 - 2147
  • [33] One of the active ingredients in Paeoniae Radix Alba functions as JAK1 inhibitor in rheumatoid arthritis
    Xiao, Lu
    Lin, Shudian
    Zhan, Feng
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [34] Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective As Monotherapy in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
    Kavanaugh, Arthur
    Ponce, Lucia
    Cseuz, Regina
    Reshetko, Olga
    Stanislavchuk, Mykola A.
    Greenwald, Maria
    Van der Aa, Annegret
    Vanhoutte, Frederic
    Tasset, Chantal
    Harrison, Pille
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [35] Dose Selection of Filgotinib, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 3 Studies: Exposure-DAS28 and ACR Modeling Approach
    Florence, Namour
    Diderichsen, Paul
    Cox, Eugene
    Sharma, Shringi
    Tasset, Chantal
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [36] Janus Kinase 1 Inhibitor INCB054707 Modulates Disease-Associated Markers and Pathways in Hidradenitis Suppurativa
    Liu, H.
    Burn, T. C.
    Jackson, J.
    Howell, M.
    Santos, L. L.
    Alavi, A.
    Smith, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (10) : S157 - S157
  • [37] MONOTHERAPY WITH THE JAK1-SELECTIVE INHIBITOR FILGOTINIB DISPLAYS AN ANTI-INFLAMMATORY BIOMARKER PROFILE IN RHEUMATOID ARTHRITIS PATIENTS
    Kavanaugh, A.
    Van der Aa, A.
    Jamoul, C.
    Li, W.
    Goyal, L.
    Pan, Y.
    Harrison, P.
    Tasset, C.
    Tarrant, J.
    Galien, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 270 - 271
  • [38] Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
    Tanaka, Yoshiya
    Atsumi, Tatsuya
    Aletaha, Daniel
    Bartok, Beatrix
    Pechonkina, Alena
    Han, Ling
    Emoto, Kahaku
    Kano, Shungo
    Rajendran, Vijay
    Takeuchi, Tsutomu
    RHEUMATOLOGY AND THERAPY, 2023, 10 (01) : 161 - 185
  • [39] Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
    Yoshiya Tanaka
    Tatsuya Atsumi
    Daniel Aletaha
    Beatrix Bartok
    Alena Pechonkina
    Ling Han
    Kahaku Emoto
    Shungo Kano
    Vijay Rajendran
    Tsutomu Takeuchi
    Rheumatology and Therapy, 2023, 10 : 161 - 185
  • [40] Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis
    Mysler, Eduardo
    Lizarraga, Ana
    RHEUMATOLOGY, 2021, 60 : II17 - II23
12345